Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Jose L Batista , Tracy Makuvire , Jonathan D Davis , et al Added: 1 month ago

Cardiovascular Kidney Metabolic

Heart Failure
Glucagon-Containing Dual and Triple Agonists For Obesity and MASH
Author(s): Scott Harris Added: 1 year ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
SGLTi and GLP-1 in HF
Author(s): Jose L Batista , Tracy Makuvire , Jonathan D Davis , et al Added: 11 months ago

Cardiovascular Kidney Metabolic

Heart Failure
James Ip

Author

Job title: MD, FHRS
ERA 25: Switching from sMRAs to Finerenone
Author(s): Beatriz Fernandez Fernandez Added: 10 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of… View more

Cardiovascular Kidney Metabolic
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 11 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Kidney Metabolic

Heart Failure
GLP-1 Medications for Patients with Moderate Peripheral Artery Disease
Author(s): Catherine Go Added: 10 months ago
Findings from a retrospective trial show GLP-1 medications for moderate peripheral artery disease (PAD) significantly decreased the risk of amputations.Dr Catherine Go (Charleston Area Medical Center, Charleston, WV, US) joins us to discuss outcomes from the largest retrospective trial evaluating the impact of GLP-1 medications for patients with moderate PAD. The study used the TriNetX database… View more

Vascular Disease and Surgery
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Oral Orforglipron Superior to Semaglutide for T2D Control
Added: 1 month ago Source:  Radcliffe CVRM
A new study has found that the novel oral GLP-1 receptor agonist, orforglipron, demonstrated superior glycaemic control compared to oral semaglutide in adults with type 2 diabetes (T2D). The findings come from the ACHIEVE-3 trial, a phase 3 study published in The Lancet.¹Mechanism of ActionOrforglipron is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-daily oral… View more

Cardiovascular Kidney Metabolic